Accessibility Menu
Turn Therapeutics logo

Turn Therapeutics

(NASDAQ) TTRX

Current Price$9.98
Market Cap$271.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+30%
5 YearN/A
1 YearN/A
1 Month+51%
Turn Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 9.122026-07-17
Turn Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.39%USD 9.442026-07-10
1 month+51.24%USD 6.032026-06-17
3 month+163.58%USD 3.462026-04-17
Year to date+131.47%USD 3.942025-12-31
Since inception+30.29%USD 7.002025-10-08

Turn Therapeutics Financials at a Glance

Market Cap

$271.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.84M

EPS (TTM)

-$0.18

P/E Ratio

-50.19

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$9.98

Volume

3,143

Open

$9.74

Previous Close

$9.98

Daily Range

$9.34 - $10.11

52-Week Range

$2.57 - $26.50

Estimated Earnings Date

Sep 2, 2026

TTRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Turn Therapeutics

Turn Therapeutics develops topical treatments for skin and nail diseases. Its products help people with eczema, fungal nail infections, and wounds. The company also licenses wound care devices to healthcare partners.

Products and Services

  • Topical Drug Candidate (GX-03): Cream for eczema and fungal nail infections; targets patients seeking alternatives to steroids and injections. (0% of revenue in 2025)
  • Medical Device Products: Wound and dermatitis care devices, including antimicrobial gauze and dressings; used by hospitals and clinics. (0% of revenue in 2025; all revenue is deferred from licensing)
  • Licensing Agreements: Out-licenses device products to partners like Medline and MiMedx; generates deferred revenue from milestone payments.
  • Exploratory Vaccine Platform: Early-stage research on nasal vaccines for infectious diseases; not yet commercialized.

Growth and Expansion

  • Signed exclusive licensing deal with MiMedx for wound care product in 2022.
  • Entered supply and co-development agreement with Medline for antimicrobial gauze in 2025.
  • Expanded product pipeline with thermostable intranasal vaccine research in 2025.
  • Increased capital through Avenue Capital loan and GEM equity agreement in 2025-2026.

What Makes Turn Therapeutics Stand Out

Turn Therapeutics uses a non-systemic, non-biologic approach, focusing on topical treatments that avoid injections and systemic side effects. Its PermaFusion process allows stable delivery of active ingredients in creams and dressings. The company operates with a lean team, relying on partnerships and outsourcing to reduce costs.

Five Things You Need to Know

  • Revenue was $0 in 2025 and 2024; all income is deferred from licensing.
  • Net loss was $(3.19) million in 2025, down from $(1.77) million in 2024.
  • Operating expenses rose to $5.86 million in 2025, up 225.6% from 2024.
  • Cash and equivalents were $5.08 million as of December 31, 2025.
  • Deferred revenue from licensing was $1.44 million at year-end 2025.

Bottom Line

Turn Therapeutics remains pre-commercial, focusing on drug development and device licensing. Its capital-efficient model and partnerships support ongoing research despite operating losses and no product sales.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2

CEO

Bradley Burnam

Website

turntherapeutics.com

Headquarters

Westlake Village, CA 91362, US

TTRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-116.83%

Return on Capital

-122.90%

Return on Assets

-20.58%

Earnings Yield

-1.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$271.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.79M

Volume

3.14K

Avg. Volume

66.86K

Financials (TTM)

Gross Profit

-$42.29K

Operating Income

-$6.72M

EBITDA

-$3.79M

Operating Cash Flow

-$3.90M

Capital Expenditure

-$10.00

Free Cash Flow

-$3.90M

Cash & ST Invst.

$11.22M

Total Debt

$6.01M

Turn Therapeutics Performance Analysis

Turn Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Turn Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Turn Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.33N/A
20232023-12-31USD -0.17-46.8%
20242024-12-31USD -0.13-23.8%
20252025-12-31USD -0.12-12.6%
Turn Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3024.7%
Q42025-12-31114.0%
Q12026-03-31-446.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$14.45K

N/A

Gross Margin

0.00%

N/A

Market Cap

$271.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$135.83M

N/A

Employees

2

N/A

Net Income

-$970.97K

-175.9%

EBITDA

-$956.52K

-171.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$11.22M

N/A

Total Debt

$6.01M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.96M

N/A

Short Term Debt

$47.80K

N/A

Return on Assets

-20.58%

N/A

Return on Invested Capital

-49.73%

N/A

Free Cash Flow

-$1.63M

N/A

Operating Cash Flow

-$1.63M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IRDOpus Genetics, Inc.
$3.05-6.73%
IKTInhibikase Therapeutics, Inc.
$2.23+5.69%
AGENAgenus Inc.
$4.97-0.80%
GLSIGreenwich LifeSciences, Inc.
$14.07-13.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
PATHUiPath
$12.16+0.00%
ZYBTZhengye Biotechnology
$8.01+10.48%
ACHRArcher Aviation
$5.31+0.20%
HLHecla Mining
$14.29-0.00%

Questions About TTRX

What is the current price of Turn Therapeutics?

Turn Therapeutics is trading at $9.98 per share.

What is the 52-week range for Turn Therapeutics?

Over the past 52 weeks, Turn Therapeutics has traded between $2.57 and $26.50.

How much debt does Turn Therapeutics have?

As of the most recent reporting period, Turn Therapeutics reported total debt of $6.01M.

How much cash does Turn Therapeutics have on hand?

Turn Therapeutics reported $11.22M in cash and cash equivalents in its most recent financial results.

What is Turn Therapeutics’s dividend yield?

Turn Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services